Eric M Ammann1,2, Matthew T Drake3, Bjarni Haraldsson1,2, Robert B Wallace1,2,4, Karen C Johnson5, Pinkal Desai6, Emily M Lin7, Brian K Link2,4. 1. Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa. 2. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa. 3. Department of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota. 4. Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa. 5. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 6. Division of Hematology and Medical Oncology, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York. 7. Department of Internal Medicine, Harbor UCLA Medical Center, Torrance, California.
Abstract
BACKGROUND: Prior evidence of a possible link between vitamin D status and hematologic malignancy (HM) in humans comes from observational studies, leaving unresolved the question of whether a true causal relationship exists. METHODS: The authors performed a secondary analysis of data from the Women's Health Initiative Calcium/Vitamin D (CaD) trial, a large randomized controlled trial of CaD supplementation compared with placebo in older women. Kaplan-Meier and Cox proportional hazards survival analysis methods were used to evaluate the relationship between treatment assignment and 1) incident HM and 2) HM-specific mortality over 10 years following randomization. HMs were classified by cell type (lymphoid, myeloid, or plasma cell) and analyzed as distinct endpoints in secondary analyses. RESULTS: A total of 34,763 Women's Health Initiative CaD trial participants (median age, 63 years) had complete baseline covariate data and were eligible for analysis. Women assigned to CaD supplementation had a significantly lower risk of incident HM (hazard ratio [HR], 0.80; 95% confidence interval [95% CI], 0.65-0.99) but not HM-specific mortality (HR, 0.77 [95% CI, 0.53-1.11] for the entire cohort; and HR, 1.03 [95% CI, 0.70-1.51] among incident HM cases after diagnosis). In secondary analyses, protective associations were found to be most robust for lymphoid malignancies, with HRs of 0.77 (95% CI, 0.59-1.01) and 0.46 (95% CI, 0.24-0.89), respectively, for cancer incidence and mortality in those assigned to CaD supplementation. CONCLUSIONS: The current post hoc analysis of data from a large and well-executed randomized controlled trial demonstrates a protective association between modest CaD supplementation and HM risk in older women. Additional research concerning the relationship between vitamin D and HM is warranted. Cancer 2017;123:4168-4177.
RCT Entities:
BACKGROUND: Prior evidence of a possible link between vitamin D status and hematologic malignancy (HM) in humans comes from observational studies, leaving unresolved the question of whether a true causal relationship exists. METHODS: The authors performed a secondary analysis of data from the Women's Health Initiative Calcium/Vitamin D (CaD) trial, a large randomized controlled trial of CaD supplementation compared with placebo in older women. Kaplan-Meier and Cox proportional hazards survival analysis methods were used to evaluate the relationship between treatment assignment and 1) incident HM and 2) HM-specific mortality over 10 years following randomization. HMs were classified by cell type (lymphoid, myeloid, or plasma cell) and analyzed as distinct endpoints in secondary analyses. RESULTS: A total of 34,763 Women's Health Initiative CaD trial participants (median age, 63 years) had complete baseline covariate data and were eligible for analysis. Women assigned to CaD supplementation had a significantly lower risk of incident HM (hazard ratio [HR], 0.80; 95% confidence interval [95% CI], 0.65-0.99) but not HM-specific mortality (HR, 0.77 [95% CI, 0.53-1.11] for the entire cohort; and HR, 1.03 [95% CI, 0.70-1.51] among incident HM cases after diagnosis). In secondary analyses, protective associations were found to be most robust for lymphoid malignancies, with HRs of 0.77 (95% CI, 0.59-1.01) and 0.46 (95% CI, 0.24-0.89), respectively, for cancer incidence and mortality in those assigned to CaD supplementation. CONCLUSIONS: The current post hoc analysis of data from a large and well-executed randomized controlled trial demonstrates a protective association between modest CaD supplementation and HM risk in older women. Additional research concerning the relationship between vitamin D and HM is warranted. Cancer 2017;123:4168-4177.
Authors: J David Curb; Anne McTiernan; Susan R Heckbert; Charles Kooperberg; Janet Stanford; Michael Nevitt; Karen C Johnson; Lori Proulx-Burns; Lisa Pastore; Michael Criqui; Sandra Daugherty Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Jennifer L Kelly; Gilles Salles; Bryan Goldman; Richard I Fisher; Pauline Brice; Oliver Press; Olivier Casasnovas; David G Maloney; Pierre Soubeyran; Lisa Rimsza; Corinne Haioun; Luc Xerri; Michael LeBlanc; Hervé Tilly; Jonathan W Friedberg Journal: J Clin Oncol Date: 2015-03-30 Impact factor: 44.544
Authors: Mark P Purdue; D Michal Freedman; Susan M Gapstur; Kathy J Helzlsouer; Francine Laden; Unhee Lim; Gertraud Maskarinec; Nathaniel Rothman; Xiao-Ou Shu; Victoria L Stevens; Anne Zeleniuch-Jacquotte; Demetrius Albanes; Kimberly Bertrand; Stephanie J Weinstein; Kai Yu; Lonn Irish; Ronald L Horst; Judith Hoffman-Bolton; Edward L Giovannucci; Laurence N Kolonel; Kirk Snyder; Walter Willett; Alan A Arslan; Richard B Hayes; Wei Zheng; Yong-Bing Xiang; Patricia Hartge Journal: Am J Epidemiol Date: 2010-06-18 Impact factor: 4.897
Authors: Peter F Schnatz; Xuezhi Jiang; Sharon Vila-Wright; Aaron K Aragaki; Matthew Nudy; David M O'Sullivan; Rebecca Jackson; Erin LeBlanc; Jennifer G Robinson; James M Shikany; Catherine R Womack; Lisa W Martin; Marian L Neuhouser; Mara Z Vitolins; Yiqing Song; Stephen Kritchevsky; JoAnn E Manson Journal: Menopause Date: 2014-08 Impact factor: 2.953
Authors: Hun Ju Lee; Josephia R Muindi; Wei Tan; Qiang Hu; Dan Wang; Song Liu; Gregory E Wilding; Laurie A Ford; Sheila N J Sait; Annemarie W Block; Araba A Adjei; Maurice Barcos; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Candace S Johnson; Donald L Trump; Meir Wetzler Journal: Cancer Date: 2013-10-25 Impact factor: 6.860
Authors: Rowan T Chlebowski; Karen C Johnson; Charles Kooperberg; Mary Pettinger; Jean Wactawski-Wende; Tom Rohan; Jacques Rossouw; Dorothy Lane; Mary Jo O'Sullivan; Shagufta Yasmeen; Robert A Hiatt; James M Shikany; Mara Vitolins; Janu Khandekar; F Allan Hubbell Journal: J Natl Cancer Inst Date: 2008-11-11 Impact factor: 13.506
Authors: Assel G Zhumina; Konstantin Li; Anna A Konovalova; Yelena A Li; Margarita Yu Ishmuratova; Gayane P Pogossyan; Michael Danilenko Journal: Nutrients Date: 2020-04-26 Impact factor: 5.717